Table 4.
HBV virologic response to lamivudine-based ART over 18 months of follow-up.
| ID | HIV RNA | Baseline | HBV DNA | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 6 | Month 12 | HBsAg | Anti-HBs | Anti-HBc | HBV DNA | 6-Month Follow-Up | 12-Month Follow-Up | 18-Month Follow-Up | |||||||
| HBV DNA | HBsAg | Mutation | HBV DNA | HBsAg | Mutation | HBV DNA | Mutation | |||||||||
| ZA265 | 410,000 | < 50 | < 50 | + | − | − | > 1.10 × 108 | 7.36 × 102 | + | 1.52 × 105 | + | 2.49 × 104 | ||||
| ZA320 | 171,533 | < 50 | < 50 | - | − | + | > 1.10 × 108 | 1.05 × 104 | + | A181T | > 1.10 × 108 | ND | 3.48 × 107 | |||
| ZA177 | 23,000 | ND | ND | − | − | + | 3.61 × 101 | < 6.00 × 100 | + | 9.68 × 100 | ND | TND | ||||
| ZA024 | 51,000 | 74,784 | ND | − | + | + | 4.46 × 103 | < 6.00 × 100 | − | > 6.00 × 100 | − | 5.85 × 101 | ||||
| ZA013 | 97,000 | < 50 | < 50 | − | + | + | 2.95 × 102 | TND | − | TND | − | 7.91 × 100 | ||||
| ZA467 | ND | ND | ND | + | − | − | 3.10 × 10 | < 6.00 × 100 | ND | TND | ND | TND | ||||
| ZA117 | ND | < 25 | 55 | + | − | − | 7.94 × 104 | 7.5 × 100 | − | 5.73 × 102 | − | TND | ||||
| ZA113 | 750,000 | 147 | < 50 | + | − | + | 1.99 × 104 | 2.23 × 105 | ND | 8.76 × 103 | ND | L180M | 7.08 × 106 | L180MM204V | ||
ND = not done; TND = target not detected.